New drug Hemay181 tested in patients with advanced cancers
NCT ID NCT07446816
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called Hemay181 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goal is to see if the drug can shrink tumors and to check for side effects. Participants will receive the drug and be monitored closely for safety and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xinxiang Medical University First Affiliated Hospital
RECRUITINGXinxiang, Henan, 45310, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?